TheStreet upgraded shares of Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP) from a sell rating to a hold rating in a research note published on Thursday.

Shares of Titan Pharmaceuticals (OTCMKTS:TTNP) traded down 0.33% during mid-day trading on Thursday, reaching $5.96. The company’s stock had a trading volume of 49,852 shares. The company has a 50 day moving average price of $5.75 and a 200 day moving average price of $5.61. Titan Pharmaceuticals has a 12 month low of $2.57 and a 12 month high of $8.74. The stock has a market capitalization of $126.34 million and a P/E ratio of 20.14.

Titan Pharmaceuticals (OTCMKTS:TTNP) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.56 by $0.02. The company earned $15 million during the quarter, compared to the consensus estimate of $15 million. On average, equities research analysts anticipate that Titan Pharmaceuticals will post $0.25 earnings per share for the current fiscal year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

In other Titan Pharmaceuticals news, Director Joseph A. Akers purchased 13,000 shares of the business’s stock in a transaction on Tuesday, July 19th. The shares were purchased at an average cost of $4.85 per share, with a total value of $63,050.00. Following the transaction, the director now directly owns 8,000 shares of the company’s stock, valued at approximately $38,800. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Sunil Bhonsle purchased 10,000 shares of the business’s stock in a transaction on Monday, July 18th. The shares were acquired at an average cost of $4.96 per share, for a total transaction of $49,600.00. Following the completion of the transaction, the chief executive officer now directly owns 135,578 shares in the company, valued at $672,466.88. The disclosure for this purchase can be found here.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.

Receive News & Ratings for Titan Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.